Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;59(9):3002-3025.
doi: 10.1111/trf.15344. Epub 2019 May 29.

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Chintamani Atreya  1 , Simone Glynn  2 , Michael Busch  3 , Steve Kleinman  4 , Edward Snyder  4 , Sara Rutter  5 , James AuBuchon  6 , Willy Flegel  7 , David Reeve  8 , Dana Devine  9 , Claudia Cohn  9 , Brian Custer  3 , Raymond Goodrich  10 , Richard J Benjamin  11 , Anna Razatos  12 , Jose Cancelas  13 , Stephen Wagner  8 , Michelle Maclean  14 , Monique Gelderman  15 , Andrew Cap  16 , Paul Ness  17
Affiliations

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Chintamani Atreya et al. Transfusion. 2019 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SK is a consultant to Cerus, manufacturer of the Intercept system and serves on Medical Advisory Board of Creative Testing Solutions (CTS). ES is PI for the Cerus PIPER Phase IV clinical study at the Yale site—he receives no personal remuneration. SR has nothing to disclose. WF states that the views expressed do not necessarily represent the view of the National Institutes of Health, the Department of Health and Human Services, or the US Federal Government and no financial relationship relevant for this publication. RB is an employee and stockholder in Cerus Corporation, a manufacturer of pathogen reduction technologies. AR is an employee of Terumo BCT.

Figures

Figure 1
Figure 1
Per‐unit infectious risk for HBV, HCV, and HIV from 1980 to 2018 and emerging infectious agents that were investigated for potential TT over the past 25 years. Agents proven to be blood safety threats for which interventions were implemented are in red, agents that were established to be legitimate infectious agents but not TT or associated with diseases are in blue, and alleged threats that were determined to not cause human infections or due to artifacts are shown in green. No interventions for HEV have yet been implemented in the United States, but interventions have been implemented in some countries where HEV incidence is higher. ICL = idiopathic CD4+ T‐lymphocytopenia; HGV = hepatitis G virus; SFV = simian foamy virus; PTLV = primate T‐cell lymphotrophic viruses; SARS = severe acute respiratory syndrome; PARV‐4 = parvovirus type 4; SFTSV = severe fever with thrombocytopenia virus; MERS‐CoV = Middle Eastern respiratory syndrome coronavirus; Ab = antibody; Ag = antigen; HBsAg = hepatitis B surface antigen; vCJD = variant Creutzfeldt‐Jakob disease. This figure was updated from Perkins and Busch.1 [Color figure can be viewed at http://wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Perkins HA, Busch MP. Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010;50:2080‐99. - PubMed
    1. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV‐1 and HCV infections among antibody‐negative blood donors by nucleic acid‐amplification testing. N Engl J Med 2004;351:760‐8. - PubMed
    1. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454‐89. - PubMed
    1. Busch MP, Bloch EM, Kleinman SH. Prevention of transfusion transmitted infections. Blood. 2019;133(17):1854‐64. - PubMed
    1. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(Suppl 2):1S‐29S. - PubMed

Publication types

MeSH terms